Serum Vitamin B12 in Relation to Anaemia and Neuropathy by MNSI among Type 2 Diabetes

Abstract

Background: Hematological and neurological symptoms can be signs of B12 inadequacy. This work was intended to evaluate the severity of B12 deficiency and link it to peripheral neuropathy (PN) and anaemia in type 2 diabetes mellitus (T2DM) adults who were using metformin. Methods: To assess PN, the Michigan Neuropathy Screening Instrument (MNSI) directed a hospital-based cross-sectional investigation of 245 adults with T2DM who were taking metformin. 155 subjects who fulfilled the insertion and rejection criteria provided fasting blood samples for measurement of vitamin B12, haemoglobin, HbA1c, and cell morphology using chemiluminescent enzyme immunoassay (C.L.I.A), high performance liquid chromatography (HPLC), and C.B.C respectively. Results: Among adults with T2DM taking metformin, B12 deficiency (B12< 200pg/ml) was prevalent in 52% cases. O.R of vegetarian diet and B12 insufficiency was 2.33 (C.I. 1.22-4.47) (p < 0.05). Despite the fact that there were no cases of macrocytic anaemia, 40% of people had anaemia, which was not related to a B12 deficiency. According to ROC analysis, serum B12 has emerged as a fair test to predict PN scores of 2.25 (p < 0.001). 38% of people had PN (PN score ≥ 2.5) Conclusions: The usage of metformin was linked to biochemical B12 insufficiency. B12 deficiency was likely to result in PN scores ≥ 2.5 on the MNSI. In T2DM individuals using metformin, serum B12 screening and the use of MNSI for PN are suggested.

Keywords

• metformin
• b12 deficiency
• neuropathy
• mnsi
• anemia
• type 2 diabetes mellitus